# XTL Biopharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2021

- Company: [XTL Biopharmaceuticals Ltd](/companies/xtlb.md) (CIK 1023549)
- Form: 20-F
- Filed: 2022-03-30
- Accepted by EDGAR: Mar 30, 2022, 21:13 ET
- Period: 2021-12-31
- Accession: 0001213900-22-016244
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1023549/000121390022016244/f20f2021_xtlbiopharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1023549/000121390022016244/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | −$1.0m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | $435.0k | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | $0.00 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | $0.00 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −$1.0m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2021-12-31 | $3.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2021-12-31 | $6.2m | ifrs-full:CurrentAssets |
| Total assets | at 2021-12-31 | $6.6m | ifrs-full:Assets |
| Shareholders' equity | at 2021-12-31 | $5.3m | ifrs-full:Equity |
| Shares outstanding | at 2021-12-31 | 544,906,149 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1023549/000121390022016244/f20f2021_xtlbiopharma.htm

Filed Mar 30, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-016244. Last ingested by Listed: Oct 24, 2026, 15:02 ET. No prices; not investment advice.